/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Disc Medicine Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$91.33 0.0296(2.96%) IRON at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 90.83
Highest Today 92.53
Today’s Open 91.17
Prev. Close 89.72
52 Week High 97.12
52 Week Low 30.82
Day’s Range: Low 90.83 High 92.53
52-Week Range: Low 30.82 High 97.12
1 day return -
1 Week return -0.83
1 month return +7.3
3 month return +53.48
6 month return +95.01
1 year return +43.23
3 year return +433.93
5 year return -8.99
10 year return -

Institutional Holdings

Market Status

Strong Buy: 8

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3386.94 M

PB Ratio 6.0366

PE Ratio 0.0

Enterprise Value 2876.37 M

Total Assets 496.77 M

Volume 389501

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-64094000 -64.1M, FY22:-46090000 -46.1M, FY21:-41005000 -41.0M, FY20:-47663000 -47.7M

Quarterly Revenue Q3/2025:7905065 7.9M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-87000 -0.1M, Q2/2025:-85000 -0.1M, Q1/2025:-20000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-110000 -0.1M

Quarterly Net worth Q3/2025:-62321000 -62.3M, Q2/2025:-55247000 -55.2M, Q1/2025:-34085000 -34.1M, Q3/2024:-26599000 -26.6M, Q2/2024:-26352000 -26.4M

Fund house & investment objective

Company Information Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 142

Industry Biotechnology

CEO Dr. John D. Quisel Esq., J.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow